MedCity News

FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer

Amazon Adds Teladoc Health to Health Benefits Program

Teladoc Health has joined Amazon's Health Benefits Connector. Other companies offered through the program include Hinge Health, Rula, Talkspace and Omada.

By Marissa Plescia

Hospitals Providers,

What’s In Store for Hospital M&A in 2025?

This year will likely see a high rate of divesture among hospital M&A deals, according to Anu Singh, managing director at Kaufman Hall. He also predicted that health systems will continue to pursue partnerships with a broader array of organizations, such as payers and venture firms, to solve challenges.

By Katie Adams

MedCity Influencers

Late to APP Reporting? Untangle Your ACO’s Optimal Method

Reporting quality on all beneficiaries marks a major shift, requiring thoughtful preparation and strategic planning. If your Accountable Care Organization (ACO) hasn’t started yet, don’t worry — there’s still time to get on track.

By Theresa (Terry) Hush

Latest News

MedCity Influencers

Precision Medicine: Becoming More Real With AI?

With technology advancements specifically in the field of AI, there is a clear line of sight in making it mainstream. Here are some of the ways AI is helping to accelerate the adoption of PM.

By Vrinda Khurjekar

Events

Join the Healthcare Innovation Conversation at MedCity INVEST

The boutique event, scheduled for May 20-21 in Chicago, offers engaging discussions on emerging trends in healthcare and networking opportunities.

By Stephanie Baum

The Funding Model for Cancer Innovation is Broken — We Can Fix It

Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.

By Eve McDavid - CEO of Mission-Driven Tech

A Checklist to Help Healthcare Practices Thrive

A new report from Relatient highlights ways hospitals and physician practices can improve workflows and how to create frictionless patient interactions.

By Stephanie Baum

Pharma BioPharma,

Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation

Galapagos and Gilead Sciences have both evolved since inking their R&D collaboration agreement in 2019. Separating Galapagos into two offers a way for that company to pursue its cell therapy strategy while also keeping the Gilead alliance alive, executives from both companies said.

By Frank Vinluan

Startups, Devices & Diagnostics

Meet the Company Developing an At-Home Test to Replace the Pap Smear

Teal Health raised $10 million in seed funding, taking its total funding to $23 million. The company has submitted an application to the FDA for its at-home cervical cancer screening kit, which seeks to give patients an alternative to the in-office pap smear.

By Katie Adams

Healthcare

Using Data to Help Healthcare Practices Succeed

A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.

By Relatient

BioPharma

Pfizer CEO At JPM Issues Clear Warning to Kennedy on Vaccines

Albert Bourla and other healthcare CEOs talked about the efficacy of vaccines and how public health could take a big turn for the worse if the incoming Trump administration veered away from accepted norms regarding vaccines.

By Arundhati Parmar

Health Tech

Form Health Unveils New Program to Prevent the Transition from Overweight to Obesity

Form Health launched a new program for people who are overweight that includes meetings with a registered dietitian and a personalized care plan.

By Marissa Plescia

MedCity Influencers

From Paper Charts to AI Scribes: The EHR Revolution

AI solutions baked into the EHR experience could radically transform the clinical effectiveness of physicians by leveraging the richness of the longitudinal patient record, while also creating efficiencies that give them back more time to care and create more revenue.

By Dr. Sara Pastoor

MedCity Influencers

The Near-Term Future of AI in Health Care

Contrary to fears of clinician replacement, AI’s near-term potential lies in complementing human expertise, particularly by handling behind-the-scenes tasks that improve efficiency and precision. Here’s where we might see the most impact.

By David Schummers

Health Tech

Providence Spun Out Its VC Arm So It Can Partner with Other Health Systems

Providence spun off its venture capital arm and renamed it Allumia Ventures. The newly independent venture capital firm also recently closed its third fund, in which Providence invested $150 million. Allumia is looking to grow the fund by inviting 3-5 other health systems to be limited partner investors.

By Katie Adams

Legal

Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions.

By Marissa Plescia

MedCity Influencers

Tech-driven Heart Care Key to Cardiology Desert Crisis

The good news is that virtual solutions are becoming more sophisticated every day to eliminate these care deserts. These promising strategies are helping.

By Frank McGillin

MedCity Influencers

Is ‘Big Data’ the Cure-all for U.S. Healthcare?

AI/big data haven't solved healthcare's challenges. Despite advancements, systemic barriers persist, but AI offers potential to improve outcomes and efficiency.

By Peter Bonis and Jim Weinstein

BioPharma, Pharma

At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected

Revenue for the blockbuster Eli Lilly drugs Mounjaro and Zepbound continues to grow, but not as much as expected. At the J.P. Morgan Healthcare Conference, Lilly CEO David Ricks explained why the company revised downward its projections for fourth quarter 2024 revenue.

By Frank Vinluan